Cargando…
Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone
Background: The evidence for the efficacy of glucocorticoids combined with tocilizumab (TCZ) in COVID-19 comes from observational studies or subgroup analysis. Our aim was to compare outcomes between hospitalized COVID-19 patients who received high-dose corticosteroid pulse therapy and TCZ and those...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746130/ https://www.ncbi.nlm.nih.gov/pubmed/35011938 http://dx.doi.org/10.3390/jcm11010198 |
_version_ | 1784630510899691520 |
---|---|
author | Belhassen-García, Moncef Sánchez-Puente, Antonio Dorado-Díaz, Pedro-Ignacio López-Bernús, Amparo Sampedro-Gómez, Jesús Azibeiro-Melchor, Raúl Marcano-Millán, Edgard Rodríguez-Alonso, Beatriz Sánchez-Barrado, María-Elisa Hernández-García, Ignacio Madruga, Ignacio Hernández-Pérez, Guillermo Carbonell, Cristina García-Aparicio, Judit Burgos, Laura López-Sánchez, Eugenia Reina, Carlos Ramón, Ana-María Cestero-Ramírez, Laura Boumhir, Fátima Encinas-Sánchez, Daniel Sánchez-Ledesma, María Herráez, Jacinto Araoz, Patricia Sánchez-Crespo, María-José Rodríguez-Rodríguez, Sandra Rodríguez-Gude, Ana-Elisa Sánchez-Hernández, Miguel-Vicente Borrás, Rafael Sagredo-Meneses, Víctor Sánchez, Pedro-Luis Marcos, Miguel Martín-Oterino, José-Ángel |
author_facet | Belhassen-García, Moncef Sánchez-Puente, Antonio Dorado-Díaz, Pedro-Ignacio López-Bernús, Amparo Sampedro-Gómez, Jesús Azibeiro-Melchor, Raúl Marcano-Millán, Edgard Rodríguez-Alonso, Beatriz Sánchez-Barrado, María-Elisa Hernández-García, Ignacio Madruga, Ignacio Hernández-Pérez, Guillermo Carbonell, Cristina García-Aparicio, Judit Burgos, Laura López-Sánchez, Eugenia Reina, Carlos Ramón, Ana-María Cestero-Ramírez, Laura Boumhir, Fátima Encinas-Sánchez, Daniel Sánchez-Ledesma, María Herráez, Jacinto Araoz, Patricia Sánchez-Crespo, María-José Rodríguez-Rodríguez, Sandra Rodríguez-Gude, Ana-Elisa Sánchez-Hernández, Miguel-Vicente Borrás, Rafael Sagredo-Meneses, Víctor Sánchez, Pedro-Luis Marcos, Miguel Martín-Oterino, José-Ángel |
author_sort | Belhassen-García, Moncef |
collection | PubMed |
description | Background: The evidence for the efficacy of glucocorticoids combined with tocilizumab (TCZ) in COVID-19 comes from observational studies or subgroup analysis. Our aim was to compare outcomes between hospitalized COVID-19 patients who received high-dose corticosteroid pulse therapy and TCZ and those who received TCZ. Methods: A retrospective single-center study was performed on consecutive hospitalized patients with severe COVID-19 between 1 March and 23 April 2020. Patients treated with either TCZ (400–600 mg, one to two doses) and methylprednisolone pulses (MPD-TCZ group) or TCZ alone were analyzed for the occurrence of a combined endpoint of death and need for invasive mechanical ventilation during admission. The independence of both treatment groups was tested using machine learning classifiers, and relevant variables that were potentially different between the groups were measured through a mean decrease accuracy algorithm. Results: An earlier date of admission was significantly associated with worse outcomes regardless of treatment type. Twenty patients died (27.0%) in the TCZ group, and 33 (44.6%) died or required intubation (n = 74), whereas in the MPD-TCZ group, 15 (11.0%) patients died and 29 (21.3%) patients reached the combined endpoint (n = 136; p = 0.006 and p < 0.001, respectively). Machine learning methodology using a random forest classifier confirmed significant differences between the treatment groups. Conclusions: MPD and TCZ improved outcomes (death and invasive mechanical ventilation) among hospitalized COVID-19 patients, but confounding variables such as the date of admission during the COVID-19 pandemic should be considered in observational studies. |
format | Online Article Text |
id | pubmed-8746130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87461302022-01-11 Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone Belhassen-García, Moncef Sánchez-Puente, Antonio Dorado-Díaz, Pedro-Ignacio López-Bernús, Amparo Sampedro-Gómez, Jesús Azibeiro-Melchor, Raúl Marcano-Millán, Edgard Rodríguez-Alonso, Beatriz Sánchez-Barrado, María-Elisa Hernández-García, Ignacio Madruga, Ignacio Hernández-Pérez, Guillermo Carbonell, Cristina García-Aparicio, Judit Burgos, Laura López-Sánchez, Eugenia Reina, Carlos Ramón, Ana-María Cestero-Ramírez, Laura Boumhir, Fátima Encinas-Sánchez, Daniel Sánchez-Ledesma, María Herráez, Jacinto Araoz, Patricia Sánchez-Crespo, María-José Rodríguez-Rodríguez, Sandra Rodríguez-Gude, Ana-Elisa Sánchez-Hernández, Miguel-Vicente Borrás, Rafael Sagredo-Meneses, Víctor Sánchez, Pedro-Luis Marcos, Miguel Martín-Oterino, José-Ángel J Clin Med Article Background: The evidence for the efficacy of glucocorticoids combined with tocilizumab (TCZ) in COVID-19 comes from observational studies or subgroup analysis. Our aim was to compare outcomes between hospitalized COVID-19 patients who received high-dose corticosteroid pulse therapy and TCZ and those who received TCZ. Methods: A retrospective single-center study was performed on consecutive hospitalized patients with severe COVID-19 between 1 March and 23 April 2020. Patients treated with either TCZ (400–600 mg, one to two doses) and methylprednisolone pulses (MPD-TCZ group) or TCZ alone were analyzed for the occurrence of a combined endpoint of death and need for invasive mechanical ventilation during admission. The independence of both treatment groups was tested using machine learning classifiers, and relevant variables that were potentially different between the groups were measured through a mean decrease accuracy algorithm. Results: An earlier date of admission was significantly associated with worse outcomes regardless of treatment type. Twenty patients died (27.0%) in the TCZ group, and 33 (44.6%) died or required intubation (n = 74), whereas in the MPD-TCZ group, 15 (11.0%) patients died and 29 (21.3%) patients reached the combined endpoint (n = 136; p = 0.006 and p < 0.001, respectively). Machine learning methodology using a random forest classifier confirmed significant differences between the treatment groups. Conclusions: MPD and TCZ improved outcomes (death and invasive mechanical ventilation) among hospitalized COVID-19 patients, but confounding variables such as the date of admission during the COVID-19 pandemic should be considered in observational studies. MDPI 2021-12-30 /pmc/articles/PMC8746130/ /pubmed/35011938 http://dx.doi.org/10.3390/jcm11010198 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Belhassen-García, Moncef Sánchez-Puente, Antonio Dorado-Díaz, Pedro-Ignacio López-Bernús, Amparo Sampedro-Gómez, Jesús Azibeiro-Melchor, Raúl Marcano-Millán, Edgard Rodríguez-Alonso, Beatriz Sánchez-Barrado, María-Elisa Hernández-García, Ignacio Madruga, Ignacio Hernández-Pérez, Guillermo Carbonell, Cristina García-Aparicio, Judit Burgos, Laura López-Sánchez, Eugenia Reina, Carlos Ramón, Ana-María Cestero-Ramírez, Laura Boumhir, Fátima Encinas-Sánchez, Daniel Sánchez-Ledesma, María Herráez, Jacinto Araoz, Patricia Sánchez-Crespo, María-José Rodríguez-Rodríguez, Sandra Rodríguez-Gude, Ana-Elisa Sánchez-Hernández, Miguel-Vicente Borrás, Rafael Sagredo-Meneses, Víctor Sánchez, Pedro-Luis Marcos, Miguel Martín-Oterino, José-Ángel Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone |
title | Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone |
title_full | Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone |
title_fullStr | Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone |
title_full_unstemmed | Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone |
title_short | Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone |
title_sort | date of admission during covid-19 pandemic impacted patient outcomes in addition to the higher efficacy of tocilizumab plus high-dose corticosteroid therapy compared to tocilizumab alone |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746130/ https://www.ncbi.nlm.nih.gov/pubmed/35011938 http://dx.doi.org/10.3390/jcm11010198 |
work_keys_str_mv | AT belhassengarciamoncef dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT sanchezpuenteantonio dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT doradodiazpedroignacio dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT lopezbernusamparo dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT sampedrogomezjesus dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT azibeiromelchorraul dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT marcanomillanedgard dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT rodriguezalonsobeatriz dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT sanchezbarradomariaelisa dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT hernandezgarciaignacio dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT madrugaignacio dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT hernandezperezguillermo dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT carbonellcristina dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT garciaapariciojudit dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT burgoslaura dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT lopezsanchezeugenia dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT reinacarlos dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT ramonanamaria dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT cesteroramirezlaura dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT boumhirfatima dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT encinassanchezdaniel dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT sanchezledesmamaria dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT herraezjacinto dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT araozpatricia dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT sanchezcrespomariajose dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT rodriguezrodriguezsandra dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT rodriguezgudeanaelisa dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT sanchezhernandezmiguelvicente dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT borrasrafael dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT sagredomenesesvictor dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT sanchezpedroluis dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT marcosmiguel dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone AT martinoterinojoseangel dateofadmissionduringcovid19pandemicimpactedpatientoutcomesinadditiontothehigherefficacyoftocilizumabplushighdosecorticosteroidtherapycomparedtotocilizumabalone |